Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial

SWORD independently evaluated a related radiotherapy–immunotherapy–cytokine combination in a multicenter phase II program.

Radiation oncology (London, England) · Sep 15, 2021
Original authors: Jianjiao Ni, Yue Zhou, Lin Wu, Xinghao Ai, Xiaorong Dong, Qian Chu, Chengbo Han, Xiaofei Wang, Zhengfei Zhu

Related research: included for context and not presented as a PRaG-series trial.

Who was studied?

20 patients with metastatic NSCLC after first-line chemotherapy.

What does the publication report?

No dose-limiting toxicities were observed in the safety run-in cohort; this report primarily addresses tolerability.

Safety findings

18 patients had treatment-related events; two grade 3 events were reported. No grade 4 or 5 events were observed.

How should we interpret it?

Small, nonrandomized safety cohort. This separate trial should not be presented as a PRaG-series trial.

Read the original source

This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.

Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.